Articles amb requisits d'accés públic - Peter RieckmannMés informació
No estan disponibles en cap lloc: 12
New perspectives in the natural history of multiple sclerosis
H Tremlett, Y Zhao, P Rieckmann, M Hutchinson
Neurology 74 (24), 2004-2015, 2010
Requisits: Canadian Institutes of Health Research
Rapid-onset central motor plasticity in multiple sclerosis
D Zeller, K Aufm Kampe, A Biller, K Stefan, R Gentner, A Schutz, ...
Neurology 74 (9), 728-735, 2010
Requisits: German Research Foundation
Interferon-β is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells
M Buttmann, F Berberich-Siebelt, E Serfling, P Rieckmann
Journal of vascular research 44 (1), 51-60, 2007
Requisits: German Research Foundation
Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts
E Kingwell, AL Leung, E Roger, P Duquette, P Rieckmann, H Tremlett
Journal of the neurological sciences 292 (1-2), 57-62, 2010
Requisits: Canadian Institutes of Health Research
Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975–2009)
A Shirani, Y Zhao, E Kingwell, P Rieckmann, H Tremlett
Multiple Sclerosis Journal 18 (4), 442-450, 2012
Requisits: Canadian Institutes of Health Research
Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration
M Buttmann, A Lorenz, A Weishaupt, P Rieckmann
Journal of neurochemistry 102 (4), 1001-1008, 2007
Requisits: German Research Foundation
Analysis of the C/T−1 single nucleotide polymorphism in the CD40 gene in multiple sclerosis
D Buck, A Kroner, P Rieckmann, M Mäurer, H Wiendl
Tissue antigens 68 (4), 335-338, 2006
Requisits: German Research Foundation
Targeting progressive neuroaxonal injury: lessons from multiple sclerosis
A Bar-Or, P Rieckmann, A Traboulsee, VW Yong
CNS drugs 25 (9), 783-799, 2011
Requisits: US National Institutes of Health, Canadian Institutes of Health Research
Characteristics of multiple sclerosis in aboriginals living in British Columbia, Canada
J Saeedi, P Rieckmann, I Yee, H Tremlett, UBC MS clinic neurologists
Multiple Sclerosis Journal 18 (9), 1239-1243, 2012
Requisits: Canadian Institutes of Health Research
Disease onset in familial and sporadic primary progressive multiple sclerosis
M Koch, Y Zhao, I Yee, C Guimond, E Kingwell, P Rieckmann, ...
Multiple Sclerosis Journal 16 (6), 694-700, 2010
Requisits: Canadian Institutes of Health Research
MS susceptibility is not affected by single nucleotide polymorphisms in the MMP9 gene
S Nischwitz, C Wolf, TFM Andlauer, D Czamara, UK Zettl, P Rieckmann, ...
Journal of neuroimmunology 279, 46-49, 2015
Requisits: Wellcome Trust
The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset
O Amram, N Schuurman, E Randall, F Zhu, J Saeedi, P Rieckmann, I Yee, ...
Multiple sclerosis and related disorders 21, 30-34, 2018
Requisits: Canadian Institutes of Health Research, Multiple Sclerosis Society, UK …
Disponibles en algun lloc: 24
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
K Selmaj, DKB Li, HP Hartung, B Hemmer, L Kappos, MS Freedman, ...
The Lancet Neurology 12 (8), 756-767, 2013
Requisits: Canadian Institutes of Health Research
Impact of multiple sclerosis relapses on progression diminishes with time
H Tremlett, M Yousefi, V Devonshire, P Rieckmann, Y Zhao
Neurology 73 (20), 1616-1623, 2009
Requisits: Canadian Institutes of Health Research
The natural history of secondary progressive multiple sclerosis
M Koch, E Kingwell, P Rieckmann, H Tremlett
Journal of Neurology, Neurosurgery & Psychiatry 81 (9), 1039-1043, 2010
Requisits: Canadian Institutes of Health Research
IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations
F Weber, B Fontaine, I Cournu-Rebeix, A Kroner, M Knop, S Lutz, ...
Genes & Immunity 9 (3), 259-263, 2008
Requisits: National Institute of Health and Medical Research, France
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility
N Couturier, F Bucciarelli, RN Nurtdinov, M Debouverie, C Lebrun-Frenay, ...
Brain 134 (3), 693-703, 2011
Requisits: National Institute of Health and Medical Research, France
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS
E Kingwell, M Koch, B Leung, S Isserow, J Geddes, P Rieckmann, ...
Neurology 74 (22), 1822-1826, 2010
Requisits: Canadian Institutes of Health Research
Sodium intake and multiple sclerosis activity and progression in BENEFIT
KC Fitzgerald, KL Munger, HP Hartung, MS Freedman, X Montalbán, ...
Annals of neurology 82 (1), 20-29, 2017
Requisits: US National Institutes of Health
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
H Wiendl, R Gold, T Berger, T Derfuss, R Linker, M Mäurer, O Aktas, ...
Therapeutic advances in neurological disorders 14, 17562864211039648, 2021
Requisits: Swiss National Science Foundation
Les dades de publicació i de finançament es determinen automàticament per mitjà d'un programa informàtic